anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Although obesity is an important risk factor for endometrial intraepithelial neoplasia (EIN) and uterine cancer, little is known about the trends in use of weight-loss therapy for patients with obesity with EIN and uterine cancer. We examined the use of weight-loss therapy among patients with obesity with EIN and uterine cancer.
METHODS: The Merative MarketScan Database was used to identify patients aged 18-70 years who were obese and diagnosed with EIN or uterine cancer. The primary treatment for EIN or uterine cancer was categorized as either primary hysterectomy or hormonal therapy. Nutrition counseling, bariatric surgeries, and weight-management medications were identified as weight-loss therapy. We analyzed trends in the use of any weight-loss therapies with Cochran-Armitage tests. A multivariable logistic regression model was developed to examine factors associated with weight-loss therapy use.
RESULTS: Overall, 15,374 patients were identified, including 5561 (36.2%) patients with EIN and obesity, and 9813 (63.8%) patients with uterine cancer and obesity. Weight-loss therapy was utilized within 1 year after diagnosis in 480 (8.6%) patients with EIN and in 802 (8.2%) patients with uterine cancer. Use of any weight-loss therapy after diagnosis of EIN increased from 4.1% in 2009 to 12.6% in 2020 (P < .001), and the use of any weight-loss therapy after diagnosis of uterine cancer increased from 4.9% in 2009 to 11.4% in 2020 (P < .001). In a multivariable regression model, younger age and patients with high comorbidity score were associated with a higher likelihood of using any weight-loss therapy.
CONCLUSIONS: Use of weight-loss therapy has increased, however there is still a significant underuse of this adjunctive therapy in patients with obesity with EIN or uterine cancer.
The invention discloses a compound Chinese herbal medicinal orally-administrated solution for preventing scurvy of poultry. The solution comprises the following components, by weight, 5-10 parts of a smoked plum extract, 5-8 parts of a radix sanguisorbae extract, 5-8 parts of total saponins of ginseng stems and leaves, 5-8 parts of an extract of male catkins of populus x canadensis, 1-2 parts of glycyrrhizic acid, 2-3 parts of vitamin C, 1-3 parts of ethylparaben, 1-2 parts of propylparaben, and 55-75 parts of water for injection. Through proper cooperation and a synergistic effect of the five medicines, the solution has the efficacy of clearing heat and detoxifying the organism, cooling the blood and tonifying yin, and eliminating the pathogenic factors and reinforcing the healthy qi, has no side or toxic effect, and is safe to use. Vitamin C having a preferable curative effect on scurvy is added, so that the curative effect is further improved. Immunity of the organism is improved, and western medicine residues are avoided. The solution can enable the poultry to effectively expel toxin in the organism, prevent scurvy, and increase anti-virus ability of the organism, and the effective rate reaches 99.7%.
BACKGROUND: Cerebral malaria (CM) is a fatal neuroinflammatory syndrome caused (in humans) by the protozoa Plasmodium (P.) falciparum. Glial cell activation is one of the mechanisms that contributes to neuroinflammation in CM.
RESULT: By studying a mouse model of CM (caused by P. berghei ANKA), we describe that the induction of autophagy promoted p21-dependent senescence in astrocytes and that CXCL-10 was part of the senescence-associated secretory phenotype. Furthermore, p21 expression was observed in post-mortem brain and peripheral blood samples from patients with CM. Lastly, we found that the depletion of senescent astrocytes with senolytic drugs abrogated inflammation and protected mice from CM.
CONCLUSION: Our data provide evidence for a novel mechanism through which astrocytes could be involved in the neuropathophysiology of CM. p21 gene expression in blood cell and an elevated plasma CXCL-10 concentration could be valuable biomarkers of CM in humans. In the end, we believe senolytic drugs shall open up new avenues to develop newer treatment options.
1320056 Opium alkaloid antigens and antibodies F HOFFMANN-LA ROCHE & CO AG 13 May 1971 [13 May 1970] 14629/71 Heading A5B [Also in Divisions B1 and C2] An opium alkaloid antigen consisting of a carboxy-C 1-6  alkyl derivative of the phenolic hydroxy group of an opium alkaloid coupled to an immunogenic carrier material is prepared by reacting the opium alkaloid derivative with an immunogenic carrier material. The immunogenic carrier material may be a protein such as human gamma globulin, human serum albumin, rabbit serum albumin, bovine gamma globulin and bovine serum albumin; a natural or synthetic polymeric compound such as a polypeptide e.g. polylysine or a polysaccharide. The opium alkaloid may be morphine, heroin, codeine or nalorphine or a derivative thereof and the preferred carboxyalkyl derivative of an opium alkaloid is 3-O-carboxymethylmorphine. The reaction may be carried out in an aqueous reaction medium having a pH of 3 to 6.5, at 0‹C to 50‹C, using a molar excess of 30 to 10,000 of the opium alkaloid derivative, in the presence of a water-soluble coupling agent such as a carbodiimide e.g. 1-ethyl- 3-(3-dimethylaminopropyl) carbodiimide. An opium alkaloid specific antibody consisting of a gamma globulin fraction protein having a multiplicity of sites which will selectively complex with an opium alkaloid, a carboxyalkyl derivative of the phenolic hydroxy group of an opium alkaloid or an opium alkaloid antigen consisting of a carboxyalkyl derivative of the phenolic hydroxy group of the opium alkaloid coupled to an immunogenic carrier material is prepared by injecting the opium alkaloid antigen into a host animal repeatedly over a period of time until opium alkaloid specific antibody is present in the blood stream, collecting a blood sample from the host animal after the injection period is completed, separating the serium from the blood sample, precipitating the antibodies from the serum by treating the serum with a neutral salt solution e.g. ammonium sulphate and purifying the antibodies.
In a related study, we have found evidence that patients with Barrett's esophagus have a leak for oral sucrose to leave the lumen of their upper gastrointestinal tract, enter the blood, and be filtered into urine. Normally the disaccharide sucrose cannot leave the lumen of the gastrointestinal tract without being first hydrolyzed to glucose and fructose. Appearance of the disaccharide in the bloodstream suggests a paracellular leak of some type in the upper gastrointestinal tract. Once in the blood, sucrose is likewise not taken up or metabolized by the kidney but simply filtered into the urine. The amount of sucrose appearing in an overnight urine sample can be used to indicate the presence of Barrett's esophagus and/or esophagitis in a patient reporting with reflux (GERD) symptoms. The leak is presumably in the Barrett's epithelium itself. This phenomenon will be used to test if a standard 8 week therapy of Nexium in a first-time-presenting GERD patient can reduce the leak as a means of assessing the efficacy of the drug in that patient. We predict that Nexium will reduce leak in esophagitis but not Barrett's patients.

In this study, patients over 18 years of age presenting with GERD symptoms to a primary care physician, will be recruited after providing informed consent. Patients will perform a sucrose leak test the evening after their recruitment by drinking a solution of 100 gms of sucrose in 200 cc of water at bedtime, then collecting an overnight urine sample (8 hrs). Within 5 days the patient will undergo an upper endoscopy exam. The patient will then begin Nexium therapy (40 mg/day of Esomeprazole) for 8 weeks, taking the dose each morning before breakfast. After 8 weeks the patient will undergo a second sucrose leak test as described above. Urine sucrose will be determined by HPLC.
Patients undergo radiation therapy on days -5 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 of beginning day 15 of cycle 1 and utomilumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Delayed indocyanine green fluorescence imaging is under investigation in various clinical disease processes. Understanding the mechanisms of indocyanine green accumulation and retention is essential to correctly interpreting and analyzing imaging data. The purpose of this scoping review was to synthesize what is known about the mechanism of indocyanine green retention at the cellular level to better understand the clinical nuances of delayed indocyanine green imaging and identify critical gaps in our knowledge to guide future studies.
METHODS: We performed a scoping review of 7,087 citations after performing database searches of PubMed, Scopus, the Cochrane Library, and the Web of Science Core Collection electronic databases. Studies were eligible for inclusion if they were peer-reviewed original research discussing the mechanism of indocyanine green retention in the results section in disease processes involving inflammation and/or necrosis, including cancer, and were available in English. Data were extracted using Covidence software.
RESULTS: Eighty-nine studies were included in the final analysis. Several features of indocyanine green retention were identified.
CONCLUSION: We identified several mechanistic features involved in indocyanine green accumulation in diseased tissue that overall had distinct mechanisms of indocyanine green retention in tumors, nontumor inflammation, and necrosis. Our study also reveals new insights on how inflammatory infiltrate influences indocyanine green fluorescence imaging. These findings are noteworthy because they add to our understanding of how fluorescence-guided surgery may be optimized based on the pathology of interest via specific indocyanine green dosing and timing of image acquisition.
In repeat-dose oral general toxicology studies up to 13-weeks duration in rats and dogs, lazertinib induced multi-organ histologic hyperplasia at exposures approximately equivalent or greater to the human exposure at the recommended dose of 240 mg. Hyperplasia was not reversible in the mandibular lymph node in the 4-week rat study. In rats, lazertinib induced renal toxicity characterized by histologic hyperplasia and inflammation in the kidney at doses ≥ 25 mg/kg (approximately 0.9 times the human exposure at the recommended dose of 240 mg/day based on AUC), along with increased urea nitrogen and histologic papillary necrosis, tubule degeneration/regeneration, and tubule dilatation at exposures approximately 4.4 times the human exposure at the recommended dose of 240 mg/day based on AUC. Increased urea nitrogen, papillary necrosis, and tubule dilatation showed evidence of recovery. In the 13-week toxicology study in dogs, one high dose animal exhibited unilateral tubule cell renal carcinoma at 8 mg/kg/day (approximately 2 times the human exposure at the recommended dose of 240 mg/day based on AUC). Other renal findings in high dose dogs included tubule degeneration/regeneration and infarct, which showed evidence of recovery. In the 4-week toxicology study, lazertinib induced cardiac toxicity in two dogs characterized by histologic findings in the heart (degeneration/necrosis of the myocardium and vessels, fibrosis, hemorrhage, thrombus, mixed cell/vessel inflammation) at 20 mg/kg (approximately 4.8 times the clinical AUC at the 240 mg human dose). One of these dogs also exhibited increased cardiac troponin I and premature ventricular complexes. These cardiac findings were not seen after a 2-week recovery period.
FIELD: medicine.SUBSTANCE: for psychological assistance in mobilizing the internal resources of a person, the patient conducts three stages of the survey; in the first stage, the personality characteristics, subjective psychophysiological reactions, sensations and experiences of the individual are evaluated. In addition, a survey is conducted to establish the type of behavior of the individual. At the same time, the patient formulates a goal for which he wants to mobilize his efforts. At the second interviewing stage, a personality test is conducted; herewith the individual being tested selects an image of a symbol, which the individual being tested finds associated with him-/herself, from a set of images of various symbols. At the second stage of the interview, the psychologist performs tactile contact with the palm of the patient, mixes and unfolds a set of images around the patient's chosen image. At the same time, the psychologist recites the suggestion formula aimed at realizing the goal set by the patient. Then, in the third stage of the survey, the depth of the impact is estimated. The patient is treated with the aroma lamp with a mixture of two parts of bergamot essential oil, one part of the essential oil of ylang-ylang and a component selected from one part of the spruce essential oil, or one part of cedar essential oil, or one part of the juniper essential oil, or one part of the ethereal pine oil. At the same time, the duration of exposure to the suggestion is at least 40-60 minutes.EFFECT: invention allows to increase efficiency of acceptance of the formula of suggestion of the psychologist by patients with the mixed and integrated types of thinking.1 tbl, 1 ex
The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
Although there has been relatively little work on 12-step treatment for seriously mentally ill patients, extant literature indicates that dually diagnosed individuals attend traditional 12-step programs such as AA, NA, and CA at rates comparable to singly diagnosed substance abusers, and that participation is associated with decreases in substance use. Specialized 12-step programs for the dually diagnosed, developed over the past 10 years, may offer additional benefits. In order to maximize the effectiveness of specialized and traditional 12-step programs for dually diagnosed individuals, specially adapted 12-step facilitation (TSF) treatment for the dually diagnosed should be developed and tested. Standard TSF should be modified to address the special needs of dually diagnosed individuals, mesh with specialized 12-step programs available in the area, and address barriers to attendance, participation, and engagement experienced by the dually diagnosed. We have developed a modified TSF based on the Project MATCH TSF manual. Modifications to this 12 week individual therapy include: emphasis on specialized 12-step program attendance; readings primarily from specialized 12-step program literature; participation in the second session by a community specialized 12-step program member; case management to assist participants in finding and attending meetings; omission of work on the fourth step; and the addition of topics covering medication compliance and specific social skills needed to negotiate 12-step meetings. In a pilot study with 10 dually diagnosed individuals, participants showed significant decreases in substance use and significant increases in 12-step attendance after receiving the specialized TSF. Building on this pilot study, the proposed study is a larger Stage 1b study of the modified TSF for seriously mentally ill patients engaged in dual diagnosis treatment. Participants with a psychotic or major affective disorder will be randomized to modified TSF (n=90) vs. treatment as usual (n=45). Participants will be followed for a total of 48 weeks. Assessments will include rigorous diagnosis and measures of alcohol and other drug use, consequences, psychiatric symptoms, 12-step behaviors, 12-step specific and non-specific change mechanisms, and social support. Specific Aims of the study include assessment of the integrity of the planned intervention and assessment battery; tests of the effectiveness of the adapted TSF relative to treatment as usual; determination of whether psychiatric diagnosis moderates treatment response; and investigation of causal mechanisms of response to treatment.
Childhood obesity not only has a negative impact on a child's health but is also a significant risk factor for adult obesity and related metabolic disorders, making it a major global public health concern. Recent studies have revealed the crucial role of gut microbiota in the occurrence and development of obesity, in addition to genetic and lifestyle factors. In this study, we recruited 19 normal-weight children and 47 children with varying degrees of obesity. A questionnaire survey was conducted to inquire about the family background, lifestyle habits and dietary composition of the 66 children. Findings indicate that fathers of obese children tend to be obese themselves, while children with highly educated mothers are more likely to maintain a normal weight. Furthermore, overweight children tend to spend more time on electronic devices and less time on physical activities compared to their normal-weight counterparts. Obese children exhibit significant differences in breakfast and dinner dietary composition when compared to children with normal weight. Additionally, the gut microbiota of these 66 children was analyzed using 16S rRNA sequencing. Analysis of gut microbiota composition showed similar compositions among children with varying degrees of obesity, but significant differences were observed in comparison to normal-weight children. Obese children exhibited a reduced proportion of Bacteroidota and an increased proportion of Firmicutes, resulting in an elevated Firmicutes/Bacteroidota ratio. Moreover, Actinobacteriota were found to be increased in the gut microbiota of children with varying degrees of obesity. PICRUSt analysis indicated significant metabolic differences in the microbiota functions between obese and normal-weight children, suggesting the composition of gut microbiota could be a crucial factor contributing to obesity. These findings provide valuable insights for the treatment of childhood obesity.
PURPOSE: A health management device, a method thereof, and a graphic user interface are provided to efficiently supply information for health management and to induce motive of a patient. CONSTITUTION: A screen(110) displays information which request measurement of first bio information. An input unit(120) accepts input of a user who requests measurement of the first bio information. A processor(130) displays a screen measuring bio-information in response to the input of the user. The bio-information is information for obtaining a measurement value. A communication unit(150) receives information about a health management service.
The invention discloses a strain of lactococcus garvieae SHAMU-LG6 with broad-spectrum antibacterial activity and application thereof. Belongs to the technical field of microorganisms. The lactococcus garvieae is preserved in China center for type culture Collection (China center for type culture Collection), with a preservation name of Lactococcus garvieae SHAMU-LG6 and a preservation number of CCTCC No: m2023482. The lactococcus garvieae has better antagonistic activity on various MDRP. The beneficial effects are that: the invention discloses a strain with antagonistic activity on various MDRP (MDRP) found from human symbiotic bacteria/colonization flora, in particular to a strain of a lactococcus garvieae SHAMU-LG6 with broad-spectrum antibacterial activity, and the genetic background is rare. The strain secretes broad-spectrum bacteriocin and has broad-spectrum antibacterial activity on various MDRP, which lays a foundation for excavating novel antibacterial molecules with low toxicity and no harm to human bodies and brand-new structure.
Genome-wide association study identified common variants within the ALDH1A2 gene as the susceptible loci of hand osteoarthritis (HOA) in UK and Iceland populations. Located in chromosome 15, ALDH1A2 encodes aldehyde dehydrogenase family 1 member A2, which is an enzyme that catalyses the synthesis of retinoic acid from retinaldehyde. Our purposes were to replicate the association of functional variant in ALDH1A2 with the development of HOA in the Chinese population. Variant rs12915901 of ALDH1A2 was genotyped in 872 HOA patients and 1223 healthy controls. Subchondral bone samples were collected from 40 patients who had undergone a trapeziectomy, and the tissue expression of ALDH1A2 was analysed. The chi-square analysis was used to compare the frequency of genotype and risk allele between the HOA cases and controls. The Student t test was used to compare the mRNA expression of ALDH1A2 between patients with genotype AA/AG and those with genotype GG. The frequency of genotype AA was significantly higher in HOA patients than in the controls (7.6% vs. 5.1%, p = .01). The frequency of allele A was significantly higher in the patients than in the controls (28.9% vs. 24.6%, p = .005). The mRNA expression of ALDH1A2 was 1.31-folds higher in patients with genotype GG than in the patients with genotype AA/AG (0.000617 ± 0.000231 vs. 0.000471 ± 0.000198, p = .04). Variant rs12915901 of ALDH1A2 contributed to the susceptibility of HOA in the Chinese population. Allele A of rs12915901 can add to the risk of HOA possibly via down-regulation of ALDH1A2 expression.
An electrocardiography device is described that can include a main body, an adjustable cap, and a power switch. The main body can include an electrode of a plurality of electrodes configured to acquire electrical signal from a patient. The adjustable cap can include two electrodes of the plurality of electrodes. The adjustable cap can be rotatable around an axis on the main body to orient the plurality of electrodes on different locations on a body of the patient. The power switch can activate the plurality of electrodes to acquire the electrical signal from the patient. Related apparatuses, systems, methods, techniques and articles are also described.
Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
One of the art therapy techniques that can provide psychological support and healing is mandala painting. Mandala is a Sanskrit word meaning 'circle'. The purpose of the circle is to encourage meditation, concentration and integration by narrowing or limiting the visual field towards the center. In mandala painting, the individual can focus their attention on the lines, stay in the moment, separate themselves from the concerns of the past and future and ensure that they remember the consciousness of the moment again. The energy and emotions of the individual can change with the rich variety of colors used in mandala painting. It can help the individual achieve spiritual calmness by silencing the chaos and sounds that disturb them. Studies in the literature have reported that mandala painting is an effective method in reducing negative moods and anxiety in individuals. Gray-Foti found in his study that mandala painting reduced the anxiety levels of new mothers and increased their self-confidence, while Özsavran and Akyıldız found that it increased the comfort and resilience of mothers with special needs children. In a meta-analysis study evaluating the effect of mandala painting on state anxiety in adults, it was determined that it was effective in reducing anxiety. However, no study has been found investigating the effect of mandala coloring on postpartum sadness.This study was planned as a randomized controlled study to help women who experience postpartum sadness get through this period more easily.